Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HCL versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HCL versus PROCHLORPERAZINE MALEATE.
FLUPHENAZINE HCL vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine is a phenothiazine antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic system. It also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminergic effects.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
Oral: 2.5-10 mg/day in divided doses every 6-8 hours; maintenance: 1-5 mg/day. IM: 1.25-2.5 mg every 6-8 hours. Decanoate (long-acting): 12.5-25 mg IM every 2-4 weeks.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-30 hours (mean 24 hours) after IM administration; up to 9-12 hours after oral dosing due to first-pass metabolism. Steady-state reached in 5-10 days.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Primarily hepatic metabolism via CYP2D6; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~20-30% of metabolites. Renal clearance is negligible.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic